Search

BiomX got orphan drug designation from the FDA for its BX004 phage cocktail for CF P. aeruginosa. This helps lower the cost and risk of drug development through extended exclusivity, lower filing fees and access to grants.

Three research opportunities are available at the Center for Biologics Evaluation and Research, FDA in Silver Spring, Maryland. The participants' project aims to evaluate the use of phage to treat Staphyloccocus aureus colonization and/or d

Eligo Bioscience announced that the U.S. FDA has granted Orphan Drug Designation and Rare Pediatric Disease designation for EB003, their oral drug candidate for the treatment of Shiga-toxin producing bacterial infection.